September 3, 2025press

Abilita announces multi-target collaboration with Orion

Multi-year discovery collaboration applies Abilita's EMP™ platform to a series of GPCR targets selected by Orion.

Abilita Therapeutics today announced a research collaboration with Orion Corporation focused on discovering antibody therapeutics against a series of multi-span GPCR targets. Under the agreement, Abilita applies its EMP™ directed-evolution platform to stabilise targets selected by Orion, enabling downstream antibody discovery campaigns.

The collaboration extends Abilita's track record of partnerships with global pharma — joining ongoing relationships with Lilly, Amgen, Bristol Myers Squibb, GSK, and Regeneron.